The under-eye area is one of the most requested concerns in aesthetic consultations and one of the most consistently difficult to treat well. The skin beneath the eye is among the thinnest anywhere on the face. It sits over a complex anatomy of muscle, fat, and vasculature that each contribute differently to how the area looks. Products that work reliably elsewhere on the face often deliver limited results here because the tissue simply does not behave the same way.
Lumi Eyes is a treatment specifically formulated for this area. It is not a general skin quality treatment adapted for the eye region. It is a dedicated periorbital injectable product built around polydeoxyribonucleotide technology, known as PDRN, that has been calibrated for the specific tissue environment beneath and around the eye.
This article explains what Lumi Eyes is, how PDRN works, which under-eye concerns it addresses and which it does not, and what a realistic result looks like across a course of treatment.
What Lumi Eyes Is
Lumi Eyes is a branded injectable product containing PDRN, which stands for polydeoxyribonucleotide. PDRN is derived from purified salmon DNA that has been processed to remove proteins capable of triggering allergic responses, leaving behind DNA fragments with molecular weights in the range of 250 to 350 kilodaltons. These fragments are the active therapeutic component.
The product is formulated specifically for periorbital use, which means the concentration, viscosity, and overall composition are calibrated for injection into the thin, delicate dermis of the under-eye region rather than the thicker facial skin where general polynucleotide products are typically used. This specificity matters clinically because the margin for error in the periorbital area is smaller than almost anywhere else on the face. An injectable product that is appropriate for the cheek or neck may not be appropriate for the immediate sub-ocular region.
Lumi Eyes belongs to the broader family of polynucleotide treatments. Its PDRN technology shares the fundamental regenerative mechanism of the polynucleotide category while being formulated for the specific anatomical and tissue characteristics of the periorbital zone.
How PDRN Works in the Under-Eye Tissue
PDRN exerts its therapeutic effect through several concurrent biological mechanisms, all of which are relevant to the under-eye concerns patients most commonly present with.
The primary mechanism is tissue regeneration through the salvage pathway. PDRN fragments are taken up by cells in the treated tissue and used as precursor material for DNA synthesis. This supports cellular repair and renewal in tissue that has been damaged by ageing, UV exposure, or chronic inflammatory processes. The under-eye area accumulates damage from environmental exposure over years, and the cellular repair capacity of the thin dermis in this region declines with age. Providing PDRN to this tissue supports repair processes that the cells cannot fully sustain independently.
The second mechanism is adenosine A2A receptor activation. PDRN activates this specific receptor pathway, which triggers an anti-inflammatory response and simultaneously stimulates growth factor production. The growth factors stimulated through this pathway, including vascular endothelial growth factor and platelet-derived growth factor, support the formation of new capillaries and the proliferation of fibroblasts in the treated tissue. New capillary formation improves microcirculation in the under-eye dermis, which directly addresses one of the contributing mechanisms behind vascular dark circles. Fibroblast proliferation drives new collagen and elastin production, improving the structural quality and thickness of the thin periorbital skin.
A third mechanism is the inhibition of inflammatory cytokines, including tumour necrosis factor and interleukins, that drive chronic low-grade inflammation in aged skin. The anti-inflammatory action of PDRN reduces the tissue stress that contributes to accelerated deterioration of the delicate periorbital dermis over time.
These three concurrent mechanisms make PDRN in the under-eye area a genuinely regenerative treatment rather than simply a hydrating one. The tissue itself is stimulated to repair, renew, and improve in structural quality, which produces a different quality of outcome from a treatment that merely delivers moisture or fills a space.
What Under-Eye Concerns Lumi Eyes Addresses
Understanding which specific under-eye presentations Lumi Eyes genuinely addresses requires being precise about what the mechanisms described above can and cannot achieve.
Thin, crepey under-eye skin responds well to Lumi Eyes. The skin beneath the eye naturally thins with age as collagen and elastin production declines and as decades of UV exposure and repeated movement take their toll on the delicate dermis. The PDRN-driven fibroblast stimulation and collagen production directly thicken and improve the quality of this skin over a course of treatment. Skin that appeared translucent and fragile becomes visibly less so as new structural protein accumulates in the treated tissue.
Dark circles caused by skin thinning and vascular visibility are significantly addressed by Lumi Eyes. When the periorbital skin is thin enough that the orbicularis oculi muscle beneath it shows through, the result is the characteristic purple-blue discolouration that many patients describe as their dark circles. Thickening the skin through PDRN-driven regeneration reduces the visual prominence of the underlying structures. Improved microcirculation through the A2A receptor vascular pathway simultaneously addresses the vascular component of this discolouration.
Fine lines and early crepiness under the eye respond to the collagen stimulation and skin thickening effect of Lumi Eyes across a course of sessions. The improvement in the structural quality of the skin means it creases less readily at rest and appears smoother overall.
Post-inflammatory pigmentation in the periorbital area, which can occur following certain skin conditions or from chronic eye rubbing, responds to the PDRN anti-inflammatory and tissue repair mechanisms. The normalisation of melanogenesis described in clinical documentation of PDRN products reflects the ability of the treatment to address pigment irregularities that have an inflammatory component.
General under-eye fatigue, meaning the tired, dull, or shadow-affected appearance that does not resolve with rest, responds to the hydration and regenerative improvement that Lumi Eyes produces in the periorbital tissue environment.
What Lumi Eyes Does Not Address
Being clear about the limitations of Lumi Eyes is as important as describing what it does.
Lumi Eyes does not fill hollows. If the primary under-eye concern is a significant tear trough hollow where volume loss has created a deep groove between the lower eyelid and the cheek, Lumi Eyes does not provide the structural fill that hyaluronic acid tear trough filler delivers. PDRN improves tissue quality and thickness but does not replace lost volume in the anatomical sense. A patient whose main concern is a hollow tear trough will see improvement in skin quality from Lumi Eyes but not the structural correction that addresses the hollow itself.
Dark circles caused entirely by anatomical shadowing from volume loss and hollowing are not primarily a Lumi Eyes indication. The shadow cast by a hollow tear trough is a structural issue that requires structural treatment. Improving the skin quality above a significant hollow does not remove the shadow below it.
Persistent puffiness from fat herniation is not addressed by Lumi Eyes. Fat pads beneath the eye that have moved forward to create visible bags under the skin are not reduced by PDRN treatment. This is a structural concern that requires different management.
Understanding these limitations is not a criticism of Lumi Eyes. It is the honest clinical positioning that protects patients from having a treatment that cannot meet their specific need and then concluding the treatment does not work.
Who Is the Right Candidate for Lumi Eyes
The right candidate for Lumi Eyes is a patient whose primary under-eye concern is skin quality rather than structural volume or puffiness.
Patients with thin, transparent, or crepey under-eye skin are well suited. The regenerative mechanism directly addresses the tissue thinning that creates these presentations.
Patients with dark circles that have a vascular or skin thinning component, rather than being primarily from hollowing or pigmentation, respond well to Lumi Eyes. Assessing which mechanism is driving the dark circles is something your practitioner does at consultation, which is why consultation before booking is particularly important for under-eye treatment.
Patients who want to avoid the specific risks associated with tear trough filler in the periorbital area, including the Tyndall effect from superficially placed filler and the risk of vascular complications in a high-risk anatomical zone, often find Lumi Eyes a more comfortable clinical choice where their concern is skin quality rather than volume.
Patients in their late thirties and beyond whose under-eye skin has started to change noticeably in texture and transparency are the core demographic, though younger patients with hereditary thin periorbital skin also benefit.
What a Course of Treatment Looks Like
A standard Lumi Eyes course involves three to four sessions spaced two to three weeks apart. A prospective observational study on polynucleotide injections for periorbital rhytides, published in peer-reviewed literature, evaluated treatment outcomes over six months and found clinically meaningful improvements in under-eye wrinkles and patient satisfaction following a course of intradermal polynucleotide injections at this spacing.
The treatment session itself takes approximately twenty to thirty minutes. Topical numbing cream is applied before treatment to maximise comfort. The injections are placed into the thin under-eye dermis using a very fine gauge needle. Mild redness and small injection marks are normal immediately after treatment and settle within a few hours for most patients.
Results develop progressively over time. Initial improvements in hydration and reduced puffiness are typically noticeable within two to four weeks of the first session. The structural improvements from collagen production and tissue regeneration accumulate more gradually, with the most visible result typically apparent at six to twelve weeks after the final session in the course.
Maintenance sessions every four to six months sustain the regenerative environment the treatment creates and prevent gradual return to the pre-treatment baseline.
Lumi Eyes Within a Broader Under-Eye Treatment Programme
Lumi Eyes works well as a standalone under-eye treatment for patients whose primary concern is skin quality. It also integrates naturally into broader treatment programmes addressing multiple under-eye concerns simultaneously.
Where volume loss is a concurrent concern alongside skin quality decline, Lumi Eyes and tear trough filler can be used together with appropriate sequencing. The skin quality improvement from Lumi Eyes enhances the appearance of the area surrounding and overlying any structural correction from filler, and the filler provides structural support that the PDRN treatment alone cannot deliver. Sequencing and timing are important and discussed at consultation.
Where lymphatic sluggishness is contributing to puffiness alongside the skin quality concerns that Lumi Eyes addresses, combining Lumi Eyes with drainage treatment targets both mechanisms in a coordinated plan. The under-eye comparison article on this blog covers the relationship between these treatments in more detail for patients who are weighing multiple options.
Frequently Asked Questions
Is Lumi Eyes the same as tear trough filler?
No. Lumi Eyes is a PDRN polynucleotide product that improves skin quality and stimulates tissue regeneration. Tear trough filler is a hyaluronic acid product that fills and supports a hollow tear trough. They address different under-eye concerns through completely different mechanisms.
Is Lumi Eyes safe for the periorbital area?
Yes. Lumi Eyes is specifically formulated for periorbital use with a concentration and viscosity calibrated for injection into the thin under-eye dermis. The PDRN active ingredient has a long track record in medical use for tissue repair and regeneration.
How soon will I notice a difference?
Initial improvements in hydration and puffiness are typically noticeable within two to four weeks of starting treatment. Structural skin quality improvements from collagen production build over the full course and are most visible at six to twelve weeks after completing the final session.
Can I have Lumi Eyes if I have previously had tear trough filler?
In many cases, yes, depending on how recently the filler was placed and how much residual product remains. This is assessed at consultation and does not automatically preclude Lumi Eyes treatment.
How many sessions do I need?
A standard course is three to four sessions. Maintenance sessions every four to six months sustain the results.
Does Lumi Eyes hurt?
Topical numbing cream is applied before treatment. Most patients find the treatment very manageable with numbing in place. The periorbital area is sensitive, so some awareness of the injections is normal.
Can Lumi Eyes be combined with polynucleotides for the rest of the face?
Yes. A broader polynucleotide programme for the face can include Lumi Eyes as the periorbital-specific component alongside a general facial polynucleotide product used for the wider face. Your practitioner will plan the combination appropriately.
Is Lumi Eyes suitable if I have a fish allergy?
No. PDRN is derived from salmon DNA, and a known fish or seafood allergy is a contraindication. This must be disclosed at consultation before any treatment is planned.
If you want to understand whether Lumi Eyes is appropriate for your specific under-eye concerns or how it fits within a broader treatment plan, book a consultation at our Littlehampton or Hove clinic.
Book a Consultation in Littlehampton or Book a Consultation in Hove
